Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Bad Blood: The Amgen/J&J Feud Takes a Perilous Turn

This article was originally published in RPM Report

Executive Summary

The longstanding feud between Amgen and Johnson & Johnson is bubbling over into a battle of bundled rebates. The fight carries broad repercussions for the pricing of biopharmaceuticals. The dispute threatens to compromise the new ASP payment system under Medicare Part B before it really gets going. Industry observers threat that the next step may be more direct price controls.

Related Content

Relabeling EPO: Closing the Books on a Safety Issue, Opening a New Chapter at FDA
Follow the Money: Why the Democrats Won't Kill Private Medicare Plans
Part D Pricing and Subpoena Power: What the November Elections Could Mean for Wall Street
Medicare Part D Enters Phase 2: Land Rush Gives Way to Claim Jumping
Medicare Part B vs. Part D
A CERA-ous Challenge to Amgen's EPO Franchise?
Part D Becomes a Force in the Pharma Market
Part D: A Big Chance for Small PBMs
Part D Starts Slow
Fashionably Early: When to Make Your Case to CMS


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts